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Abstract
Background
Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United
States and Europe. However, most of the prospective randomized studies have very little
follow-up compared to the long natural history of the disease. The primary aim of this study
was to investigate the long-term survival of our series of patients with follicular lymphoma.
Patients and methods
A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were
prospectively enrolled from 1980 to 2013.
Results
Median follow-up was 54.9 months and median overall survival is over 20 years in our series.
We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully
assess the prognostic factors that condition this group. Out of 166 patients who are still alive
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after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease.
Variables significantly associated with survival at 10 years were stage < II (p <0.03), age <
60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symp-
toms upon diagnosis (p <0.02), Performance Status 0–1 (p <0.03) and treatment with anthra-
cyclines and rituximab (p <0.001), or rituximab (p <0.0001).
Conclusions
A longer follow-up and a large series demonstrated a substantial population of patients with
follicular lymphoma free of disease for more than 10 years.
Introduction
Follicular lymphomas (FL) are the second most common non-Hodgkin lymphoma (NHL) in
Western Europe [1], accounting for approximately 20 percent to 30 percent of all NHLs. In the
series from The Non-Hodgkin´s Lymphoma Classification Project they represent 22% [2, 3],
and 22–40% of the NHL [4, 5] according to the WHO classification.
The annual incidence of this disease has increased rapidly in the last decades, from 2–3
cases in a population of 100,000 in 1950 to 5.7 cases/100,000 in 2009. The prevalence is of
approximately 40/100.000 [6]. The incidence increases with age. Most cases occur in adults
over 50 years old and the elderly. They are rare in the third and fourth decades and exceptional
in children and adolescents. In Spain, between 3,000 and 5,000 new cases of follicular lym-
phoma are diagnosed each year. It is the second most common tumor of lymphoid lineage.
Despite recent improvements in survival, FL remains an incurable disease. About 80% of
patients with FL are diagnosed in stages III / IV. The median of the overall survival (OS) is
lengthy (about 10 years) and OS rate up to five years over 75% [7]. Additionally, transforma-
tion to more aggressive histological forms, usually diffuse large B-cell lymphoma (DLBCL),
may also occur, which implies, in general, very poor prognosis [8]. The risk of transformation
appears to be independent of the type of treatment used (or lack thereof) [9]. In autopsy series,
most cases (95%) show some evidence of transformation [10].
The course of the disease can be highly variable [11]. This is a difficult task in such an
uncommon disorder with a prolonged natural history, and almost impossible when complex
treatments such as bone marrow transplantation are concerned. In order to facilitate clinical
studies, a number of outcome biomarkers have been proposed, although none of them has a
validated correlation with survival.
The Follicular Lymphoma International Prognostic Index (FLIPI), has been proven to have
a better discriminatory power in assessing patient prognosis and seems to produce a more
even patient distribution among different risk groups compared to the International Prognos-
tic Index (IPI). The FLIPI is currently used for defining individual risk of death and the tumor
grade [12, 13, 14]. More recently, FLIPI2 [15] was developed as a new model for prognostic
definition of patients with FL. It will best fit the current reality of the problem, as it has been
developed with patients treated with immunotherapy and discriminates in groups according
to a progression-free interval of disease, which is a more appropriate variable for FL.
Patients usually have prolonged survival, with medians that can reach or exceed 10 years.
They have high response rates to different treatments, although responses are followed by
sequent relapses with a shrinking time interval. Despite this high chemosensitivity, historically,
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nor OS or disease free survival could be modified for decades, despite having employed differ-
ent therapeutic strategies.
This situation has changed in the last decade due to the introduction of chemoimmu-
notherapy, which is already reflected in some population statistics [16]. The median survival
has been increased up to 14 years and progression-free survival up to 5 years [17]. These
increases in the patients´ survival have been observed since 2003 upon the introduction of the
anti-CD20 monoclonal antibody, rituximab (R), in the chemotherapy regimens.
The purpose of the present study was to assess the clinical outcome of patients with FL
included in a Spanish registry by the Spanish Lymphoma Oncology Group (GOTEL). This
database is part of a prospective registry of all new lymphoma cases, regardless of their histo-
logical subtype, which tries to ascertain a possible clinical impact of different therapeutic strat-
egies introduced in the last decades.
Methods
Patients
The study was performed as a prospective multicenter study [18]. It was conducted in compli-
ance with the Declaration of Helsinki, and was approved by Puerta de Hierro-Majadahonda
Ethics Committee.
Patients referred to the Oncology Department of 18 Spanish hospitals between January
1980 and December 2013, diagnosed with FL were included. Information concerning demo-
graphic and clinical-pathological features of each patient as well as prognostic factors, type of
treatment and treatment outcome was collected. Patients were staged according to the Ann
Arbor system, the FLIPI was calculated, and systemic symptoms were regarded as present
when the patient had unexplained fever, night sweats, or weight loss of>10% of initial body
weight. Treatment information such as type of therapy (radiation therapy, chemotherapy,
combined therapy, or no therapy), response to therapy, and the patient’s survival status, was
collected and was assessed in months.
All patients included required a certain diagnosis of follicular lymphoma and were staged
according to the Ann Arbor system. Treatment information had to be fully documented,
including treatment modality, and initial and final doses. Patients who did not meet any of
these criteria were excluded.
The authors served as the advisory board for this study, and participated in all phases of the
study, including protocol design, data collection and analysis, and consideration of participat-
ing sites.
Statistical analysis
Overall survival was the end point of all statistical analyses. Survival rates and corresponding
standard errors were estimated using Kaplan and Meier estimators. Survival curves were com-
pared applying the log-rank test.
According to the external evaluator’s criteria and due to a lack of sufficient diagnostic, sur-
vival or follow up data, 104 patients out of the 1178 patients diagnosed with FL were excluded
from the analysis. Therefore we reviewed 1074 patients treated in our country, investigating
the use of R and exploring the association between this treatment and survival compared with
other patients treated without R in first line or watchful waiting approach in our series with
long-follow, and with a median survival of 234 months.
Statistical analyses were performed firstly in all patients and secondly in the treatment
group, where efficacy endpoints were analyzed. Overall survival times were estimated with
the Kaplan-Meier method and compared with a two-sided log-rank test. Univariate and
Impact of treatment in long-term survival patients with follicular lymphoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0177204 May 11, 2017 3 / 14
multivariate Cox regression analysis were used to assess the association between each potential
prognostic factor and overall survival and calculate the relative risk (RR). All analyses were
two-sided with a 5% significance level and were performed with SPSS version 19 and STATA
version 12.
Death hazard risk (HR) according to year of treatment and to age upon diagnosis was calcu-
lated. Correlation between group and HR was obtained with the Cox model.
Results
Patient characteristics
A total of 1178 patients diagnosed with grade I-IIIa FL between January 1980 and December
2013, in the Oncology Department of 18 Spanish hospitals, were enrolled in the FL Registry, a
prospective registry promoted by GOTEL (Spanish Lymphoma Oncology Group) that
includes all new lymphoma cases, regardless of their histological subtype. All diagnoses were
confirmed by a study hematopathologist. Exclusion criteria were: initial diagnosis of grade
IIIb, primary cutaneous FL and HIV positive.
According to the external evaluator´s criteria and due to a lack of sufficient diagnostic, sur-
vival or follow up data, 104 patients out of the 1178 patients diagnosed with LF were excluded
from the analysis.
The median follow up in the entire series was 54.9 months (1–365.0), 63.7 months (0.1–
365.3) only considering patients alive free of disease, 43.7 months (0.1–365.4) for patients alive
with the disease, and 32.5 months (0.4–228.4) for those patients who died.
The main clinical variables registered at the time of diagnosis with potential prognostic rele-
vance are reported in Table 1 and the median follow-up of surviving patients and the OS of
these patients are shown in Fig 1.
Follow-up and survival
Significant variables in univariate analysis (Table 2) for OS in our series were incorporated in a
multivariate model (Table 3). The multivariate analysis in our series shows greater significance
at 60 years of age, as well as performance status (PS), transformation and FLIPI. A cutpoint at
40 years of age was also analyzed to estimate an influence in survival. Our series shows an
increase in OS in patients under 40 years old without reaching the median survival, and of 16.3
years in patients over 40 years old, with significant statistical difference (p<0.00001) between
the curves of OS (Fig 2).
Taking as reference group the young adults group, aged 20–29 years, the risk increases in
every group, as shown in Table 4. When calculating HR in Cox model, the reference value
always corresponds to minimum risk group, aged19 years, which is why HR increases from
50 years old. Correlation between group of age and HR obtained with Cox model is presented
in Fig 3. There is no linear correlation with age, it’s a quadratic correlation. R2 shows a great
correlation between HR and age, being 94.7% the variability of HR explained by age, with less
than a 5% error.
An analysis of patients who are still alive beyond 10 years upon diagnosis was conducted, to
fully assess the prognostic factors that condition this group. In a group of 166 patients who are
still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical
disease.
The following variables were not significant: gender, number of nodal areas affected, bone
marrow involved or not, lactate dehydrogenase (LDH) levels, nodal or extranodal origin,
presence of bulky mass, hemoglobin or transformation to a more aggressive lymphoma. How-
ever, stage<II (p<0.03), age under 60 years (p<0.0001), low FLIPI (p<0.002), average B2
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Table 1. Patient characteristics.
Clinical Variables N
Sex Male 506
Female 568
Grade I 341
II 316
III 129
IIIa 131
IIIb 23
Centrofollicular cutaneous variant 12
Centrofollicular diffuse variant 50
NA 72
Origin Nodal 907
Extranodal 167
Ann Arbor stage I 141
II 157
III 273
IV 500
NA 3
ECOG 0 609
1 366
2 68
3 25
4 4
NA 2
Bone marrow involvement No 654
Yes 417
NA 3
B Symptoms No 847
Yes 224
NA 3
Bulky mass No 820
Yes 254
Number of extranodal localizations 0 602
1 357
2 115
HIV No 1072
Yes 2
Treatment CT with anthracyclines 164
CT w/o anthracyclines 98
CT with anthracyclines and R 633
CT w/o anthracyclines or R 110
R monotherapy 37
Cx 13
Observation 19
RT No 826
Yes 248
ASCT No 1017
Yes 57
(Continued )
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microglobulin (p<0.005), no B symptoms upon diagnosis (p<0.02), PS 0–1 (p<0.03) and
combined treatment with anthracyclines and R were the variables that were significantly asso-
ciated with survival at 10 years (p<0.0001) (Table 5).
The HR of death among patients has been declining progressively over the years as can be
observed in Fig 4.
Discussion
Several prognostic factors have been identified in an effort to predict the outcome in patients
with FL, including FLIPI, which divides FL cases into three groups with distinct survival prob-
abilities. FLIPI is an internationally validated prognostic index, which provides some hope for
improved categorization for patients in clinical studies. Unfortunately, it is solely based on
demographic and clinical data and is somehow limited. Alternatively, prognostic models that
incorporate biological information, such as those based on gene expression profiles, are poten-
tially much more powerful, although they require validation. Still, and despite such limitations,
Table 1. (Continued)
Clinical Variables N
Transformation No 1040
Yes 34
Type of transformation Diffuse large B cell 20
MALT 1
Hodgkin´s Lymphoma 1
Mantle B cells lymphoma 1
Follicular lymphoma grade 3 2
Burkitt like lymphoma 2
Angiocentric high grade peripheral T cells lymphoma 1
High grade follicular lymphoma 1
Unknown 5
Cause of death Primary tumour 135
Secondary tumour 21
Other 68
Hb <12 257
>12 817
LDH average 812
high 362
FLIPI 0 171
1 279
2 337
3 174
4 88
5 25
B2microglobulin average 644
high 345
NA 85
CT: chemotherapy; R: rituximab; ECOG: Eastern Cooperative Oncology Group; HIV: human
immunodeficiency virus; FLIPI: Follicular Lymphoma International Prognostic Index; Hb: hemoglobin; LDH:
lactate dehydrogenase; ASCT: autologous stem cell transplantation; RT: radiotherapy; Cx: surgery
https://doi.org/10.1371/journal.pone.0177204.t001
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progress has been made and improvements during the past decade in survival of FL patients
have been repeatedly demonstrated in randomized studies and meta-analyses.
In our series, we found significant difference between low/intermediate (<3), and high-risk
FLIPI groups (3) in terms of OS. Although currently the FLIP2 score is used, we were unable
to apply this type of score in our cases due to incomplete availability of some clinical and bio-
logical parameters, which were not routinely collected at the time of diagnosis.
The prognostic factors in our series are similar to other series [19, 20, 21] and have already
been mentioned: age, B symptoms, stage and tumor burden, extent of bone marrow infiltra-
tion, infiltration of specific organs, levels of LDH and β2 microglobulin.
Fig 1. Overall survival (in months) according to performance status ECOG (B) and FLIPI score at diagnosis (C) for all patients (n = 1074).
https://doi.org/10.1371/journal.pone.0177204.g001
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Also, we investigated alternative cutpoints of age other than the traditional 60 years.
Thereby, our series shows an increase in overall survival in patients under 40 years of age,
without reaching the median survival and those over 40 years of age of 16.3 years, with great
statistical difference (p<0.00001) between the curves of overall survival. These results are simi-
lar to those obtained in a recent study at Princess Margaret Hospital on 61 patients under 40
years of age, showing that the classic cutpoint at 60 years might not be entirely adequate; an
earlier age may reflect better prognostic factors and later ages may serve to identify causes of
Table 2. Results of univariate analysis of different prognostic factors in the whole population of 1074 patients with follicular lymphoma (FL). The
table shows the statistically significant prognostic factors.
Overall Survival N Median (95% CI) % p
Age >60 455 117,2(85.2–149.1) 38 <0.0001
Ann Arbor stage >II 730 192.1(148.7–235.5) 85,9 0.003
ECOG >1 671 NR 5,1 <0.0001
Bone marrow involvement 387 152.1(117.2–187.1) 38,6 0.006
B symptoms (NO) 767 NR 81,5 0.02
Nodal sites>4 426 176.1(149.9–202.3) 10,4 0.03
Bulky mass (YES) 239 170.4(118.2–222.7) 20,3 0.02
Extranodal sites (=1) 334 192.7(—) 32,1 0.002
RT (NO) 782 NR 69,8 0.001
ASCT (NO) 952 228.4(—) 91,8 0.07
Transformation (NO) 974 NR 95,8 0.003
Hb<12 235 192.1(—) 76,6 0.02
normal LDH 757 NR 76,8 <0.0001
FLIPI 0 157 NR 20,5 <0.0001
β2-microglobulin (normal) 598 NR 71,7 <0.0001
Treatment with anthracyclines 199 192.1(113.5–270.7) 17,7 <0.0001
RT: radiotherapy; ECOG: Eastern Cooperative Oncology Group; FLIPI: Follicular Lymphoma International Prognostic Index; Hb: hemoglobin; LDH: lactate
dehydrogenase; ASCT: autologous stem cell transplantation; NR: not representative.
https://doi.org/10.1371/journal.pone.0177204.t002
Table 3. Multivariate analysis: Characteristics associated with overall survival.
Variables HR (95% CI) p
ECOG 1 ref.
ECOG (1) 1.8(1.3–2.5) <0.0001
ECOG (2) 3.8(2.5–5.8) <0.0001
ECOG (3) 8.3(4.6–14.8) <0.0001
ECOG (4) 15.5(4.7–51.1) <0.0001
B Symptoms 1.4(1.1–1.9) 0.015
Transformation 2.6(1.5–4.5) <0.0001
FLIPI 1 ref.
FLIPI 1 2.2(1.1–4.3) 0.03
FLIPI 2 2.4(1.2–4.9) 0.01
FLIPI 3 3.6(1.8–7.5) 0.001
FLIPI 4 3.5(1.6–7.5) 0.001
FLIPI 5 4.1(1.6–10.4) 0.001
Age>60 1.9(1.5–2.7) <0.0001
ECOG: Eastern Cooperative Oncology Group; FLIPI: Follicular Lymphoma International Prognostic Index
https://doi.org/10.1371/journal.pone.0177204.t003
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Fig 2. Kaplan-Meier estimates of survival (in years) according to age (over or under 40 years of age).
https://doi.org/10.1371/journal.pone.0177204.g002
Table 4. Age distribution at time of diagnosis of follicular lymphoma for all patients. Correlation between age, mortality, and risk of death, taking as ref-
erence group the group aged 20–29 years.
Age Alive Dead N RR OR HR p
29 20 1 21 0.05 1 Ref.
30–39 64 7 71 0.09 1.8 0.47 0.54
40–49 122 12 134 0.09 1.8 0.99 0.99
50–59 128 22 150 0.15 3 1.87 0.54
60–69 128 28 156 0.18 3.6 3.23 0.25
70–79 52 30 82 0.36 7.2 7.04 0.06
80 10 3 13 0.23 4.6 5.69 0.15
RR: relative risk (of death); OR: overall risk; HR: hazard risk.
https://doi.org/10.1371/journal.pone.0177204.t004
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competitive mortality. We looked into this aspect, and our findings suggest that age gives an
increased risk of death regardless of the cut point that we use. As a matter of fact, a comparison
of clinical features at diagnosis between patients40 and>40 years was carried out in a Euro-
pean series of 1002 patients from 4 different institutions indicated that prognostic factors are
Fig 3. Correlation between group of age and HR value, obtained by Cox model. HR indicates hazard risk and R2explains the great
correlation between HR and age, with less than a 5% error.
https://doi.org/10.1371/journal.pone.0177204.g003
Table 5. Variables significantly associated with survival at 10 years.
N % p value
Ann Arbor Stage<II 44 33.3 0.03
Age<60 96 72.7 0.0001
Low FLIPI 71 53.8 0.002
Normal β2 microglobulin 89 73.6 0.05
No B symptoms 115 87.1 0.02
PS 0–1 129 97.7 0.03
Treatment CT+R 45 39.1 0.001
R monotherapy 60 45.5 <0.0001
CT: chemotherapy; R: rituximab; FLIPI: Follicular Lymphoma International Prognostic Index; PS:
performance status;
https://doi.org/10.1371/journal.pone.0177204.t005
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useful in the whole population of patients with FL and also apply to younger patients, and that
lymphoma-specific survival is similar in young adults and in patients aged 40–60 [22].
The median OS of patients diagnosed with FL is over 20 years in our series. We observed a
constant decrease in the HR of death as the years have passed, showing a best prognosis for
these patients. Of interest, we wanted to see if a percentage of PFS patients beyond 10 years
were sustained. The skill of the therapeutic group seems unlikely to be the explanation of these
results, since it is a multicenter study, and also with one of the largest published series that
gives a clear consistency to the results. Our data support the initial combined treatment with R
and anthracyclines could be considered key factors versus observation.
In 2012 a data analysis from the F2 Study Registry from the International Follicular Lym-
phoma Prognostic Factor was published. Data from this cohort was compared to patients
within the same study but initially treated with regimens that would contain R, in order to
know if an initial expectant attitude could influence the effectiveness of these treatments. The
5-year survival was similar in both groups, 87% in the group of patients under observation ver-
sus 88% in the group of patients initially treated, concluding that in the R era the strategy of
"wait and watch" remains valid for patients with favorable prognostic factors and low-grade
tumors (GELF criteria) [23, 24].
Fig 4. Adjusted death hazard rate to year of diagnosis for the Spanish Lymphoma Study.
https://doi.org/10.1371/journal.pone.0177204.g004
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First line treatment with R was introduced in Spain only since 2004. However, many
patients may have received this treatment during the course of the disease and benefit from it.
It seems that the addition of R to chemotherapy schemes has managed to modify the OS of
these patients.
Aiming to clarify it, two phase III studies were launched; the National Lympho Care Study
[25] and FOLL-05 [26]. No difference was observed in either of them between R-CHOP
(cyclophosphamide, doxorubicine, vincristine, prednisone), R-CVP (cyclophosphamide, vin-
cristine, prednisone) and R-FM (fludarabine and mitoxantrone), in terms of OS or progres-
sion-free survival. Increased time to progression (27 months vs 7 months) and longer survival
at 4 years (83% vs 77%) was also observed [27].
We observed an increase in OS of patients over the years and diagnostic times, which are
identifiable in all age and sex groups, including advanced stages. This finding is consistent
with data from American [28, 29] and European [30] studies, ours being the largest study of all
the ones published in our continent that can be related to the introduction of R. It has been
speculated whether the improvements achieved in support care or even high doses of chemo-
therapy may have influenced this.
According to our results, especially taking into account the study of patients alive for more
than 10 years, we believe that the weight of the introduction of R in a young population, associ-
ated with chemotherapy, has given these high rates of survival in an unselected population.
The median OS of patients diagnosed of FL is over 20 years in our series, which suggest that
increase in survival might be due to the use of anthracyclines, R and radiotherapy.
The development of national registries such as the Spanish Follicular Lymphoma Registry,
promoted by GOTEL, help us identify the clinical-pathological characteristics of the patients
in our area and therefore try to develop the best treatment program for our patients, improv-
ing the effectiveness of our clinical practice.
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